Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008

Journal of Bone and Mineral Research

Volumn 26, Issue 1, 2011, Pages 3-11

  Siris, Ethel S ^a   Pasquale, Margaret K ^b   Wang, Yiting ^b   Watts, Nelson B ^c  

^a Howard Hughes Medical Institute   (United States)

^b Warner Chilcott   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

COMPLIANCE; FRACTURES; MEDICATION POSSESSION RATIO; ORAL BISPHOSPHONATES; OSTEOPOROSIS

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; FRACTURE; FRACTURE REDUCTION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; UNITED STATES;

ADMINISTRATION, ORAL; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 78650962009     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.189     Document Type: Article

References (18)

1. National Osteoporosis Foundation. Disease statistics. Available at: Accessed October 1, 2009.
2. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000; 85: 4118-4124.
3. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19: 1241-1249.
4. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999; 282: 1344-1352.
5. Siris ES, Selby PL, Saag KG, Borgström F, Herings RMC, Silverman SL., Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122: S3-S13.
6. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value in Health. 2008; 11: 44-47.
7. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 U.S. claims databases. Mayo Clin Proc. 2006; 81: 1013-1022.
8. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Deizell E., Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. JBMR. 2008; 23: 1435-1441.
9. Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S., Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int. 2009; 20: 1571-1581.
10. Danese MD, Badamgarav E, Bauer DC., Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. JBMR. 2009; 24: 1819-1826.
11. Sheehy O, Kindundu C, Barbeau M, LeLorier J., Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009; 20: 1583-1594.
12. Baron JA, Karagas M, Barrett J, et al. Basic epidemiology of fractures of the upper and lower limb among Americans over 65 years of age. Epidemiology. 1996; 7: 612-618.
13. Population Division, U.S. Census Bureau. Annual estimates of the population by sex and five-year age groups for the United States. Available at:. Accessed September 1, 2009.
14. Looker AC, Johnston CC, Wahner HW, et al. Prevalence of low femoral bone density in older U.S. women from NHANES III. JBMR. 1995; 10: 796-802.
15. Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III., The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int. 2010; 21: 41-52.
16. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB., Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302: 1573-1579.
17. Nelson HD, Helfand M, Woolf SH, Allan JD., Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137: 529-541. (Pubitemid 35024625)
18. WHO Collaborating Center for Metabolic Bone Diseases, Sheffield University. Assessment of osteoporosis at the primary health care level. 2008; Sheffield University, Sheffield, UK.